TY  - JOUR
T1  - Organoid Response Maps Can Bridge Natural Product Screening and Human Therapeutics by Preserving Tissue Architecture, Heterogeneity, and Patient-Specific Biology
A1  - Ravi Kumar
A1  - Neha Sharma
A1  - Aniket Deshmukh
A1  - Sanjay Kulkarni
A1  - Arjun Nair
JF  - International Journal of Pharmaceutical And Phytopharmacological Research
JO  - Int J Pharm Phytopharmacol Res
SN  - 2250-1029
Y1  - 2026
VL  - 16
IS  - 4
DO  - 10.51847/rGAfJALuOz
SP  - 50
EP  - 59
N2  - 
Natural-product screening frequently begins in reductionist systems that efficiently identify activity but poorly preserve the tissue organization, cellular diversity, and patient-specific biology that shape therapeutic response. Human organoids offer an intermediate experimental space in which chemical perturbations can be examined within three-dimensional, disease-relevant models, yet organoid results are often reduced to single viability endpoints and remain disconnected from chemical provenance, spatial phenotype, molecular state, and clinical context. This article develops a proposed organoid response-map translational framework for integrating these dimensions without treating organoid activity as equivalent to mechanism, exposure, or clinical efficacy. The framework positions tissue architecture and heterogeneity, patient and disease identity, natural-product perturbation, imaging and omics, chemical representation, mechanism inference, and human validation as separable evidence layers that should remain linked but not collapsed. Existing studies support the feasibility of patient-derived organoid pharmacotyping, quantitative three-dimensional phenotyping, multimodal analysis, and defined clinical-response associations. Direct natural-product evidence, however, remains comparatively sparse and chemically heterogeneous. Consequently, the proposed response map is intended as an evidence-organizing and hypothesis-prioritizing construct rather than a validated predictive system. Its translational value depends on controlled compound identity and exposure, organoid fidelity, assay standardization, applicability-domain awareness, orthogonal mechanism testing, and prospective comparison with human tissue and clinical outcomes. The framework therefore aims to improve what is preserved, measured, and qualified between natural-product screening and therapeutic interpretation while making uncertainty explicit.

UR  - https://eijppr.com/article/organoid-response-maps-can-bridge-natural-product-screening-and-human-therapeutics-by-preserving-tis-9wrnc3ljhrq4hi6
ER  -